Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.

作者信息

Booth Christopher M, Eisenhauer Elizabeth A, Gyawali Bishal, Tannock Ian F

机构信息

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.

Department of Oncology, Queen's University, Kingston, Canada.

出版信息

J Clin Oncol. 2023 Nov 10;41(32):4968-4972. doi: 10.1200/JCO.23.01423. Epub 2023 Sep 21.

DOI:10.1200/JCO.23.01423

PMID:37733981

Abstract

摘要

相似文献

[1]

Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.

J Clin Oncol. 2023-11-10

[2]

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.

J Clin Oncol. 2024-3-10

[3]

Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.

JAMA Oncol. 2022-5-1

[4]

Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.

Curr Oncol Rep. 2009-1

[5]

Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.

BMJ Open. 2019-12-10

[6]

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

JAMA. 2021-3-2

[7]

Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.

Eur J Cancer. 2014-9

[8]

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.

Cancer J. 2009

[9]

Effects of cancer drugs on survival: often poorly evaluated.

Prescrire Int. 2009-8

[10]

Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

引用本文的文献

[1]

Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological Analysis.

Cancer Med. 2025-8

[2]

Bayesian interim analysis and efficiency of phase III randomized trials.

Br J Cancer. 2025-8-11

[3]

Advancing equitable access to innovation in breast cancer.

NPJ Breast Cancer. 2025-7-10

[4]

Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis.

JAMA Oncol. 2025-6-1

[5]

Strategies to reduce the cancer burden and improve access to effective and affordable cancer interventions in Europe.

Mol Oncol. 2025-6

[6]

The Impact of Beta Blockers on Survival in Cancer Patients: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2025-4-18

[7]

The UK's Early Access to Medicines Scheme 10 years on: an evaluation using publicly available data.

JRSM Open. 2025-2-24

[8]

Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial.

JCO Oncol Adv. 2025-1-30

[9]

Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending.

BMJ Oncol. 2024-1-30

[10]

Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials.

BMJ Oncol. 2024-4-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献